AbCellera Results Presentation Deck

FINANCIALS Q1 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 9 6 molecules in the clinic, 2 authorized for emergency use. MOLECULE bamlanivimab (LY-CoV555) bebtelovimab (LY-CoV1404) NBL-012 NBL-015 NEW undisclosed IVX-01 STAGE Marketed, Emergency Use Authorization (EUA) Marketed, Emergency Use Authorization (EUA) Phase I IND approved IND approved Clinical field study PARTNER Lilly Lilly NovaRock BOTHERAPEUTICS NovaRock BIOTHERAPEUTICS undisclosed Invetx™ THERAPEUTIC AREA ● ● ● ● ● ● ● ● infectious disease - COVID-19 infectious disease - COVID-19 dermatology gastrointestinal disease immunology oncology undisclosed animal health PROGRAM TYPE AbCellera Discovery Partnership Trianni License AbCellera Discovery Partnership As of March 31, 2022

View entire presentation